2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1136/annrheumdis-2017-211401 http://hdl.handle.net/11449/165531 |
Resumo: | To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (>= 30), moderate (>= 45), and major (>= 70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p= 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p< 0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement. |
id |
UNSP_1f4c735c9c2aa3ba65ade0b5d9e675e9 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/165531 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative InitiativeTo develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (>= 30), moderate (>= 45), and major (>= 70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p= 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p< 0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement.Intramural NIH HHSNIH, NIEHS, Bethesda, MD USAUniv Pittsburgh, Pittsburgh, PA 15260 USAIst Giannina Gaslini, Genoa, ItalySocial & Sci Syst Inc, Durham, NC USAHosp Sick Children, Toronto, ON, CanadaIWK Hlth Ctr, Halifax, NS, CanadaUniv Florence, Florence, ItalyUniv Buenos Aires, Hosp Ninos Pedro Elizalde, Buenos Aires, DF, ArgentinaUniv Fed Rio de Janeiro, Rio De Janeiro, BrazilUniv Kansas, Med Ctr, Kansas City, KS 66103 USAGreat Ormond St Hosp Sick Children, Children NHS Trust, London, EnglandUniv Texas Dallas, Southwester Med Ctr, Dallas, TX 75083 USAUniv Genoa, Ist Giannina Gaslini, Pediatria Reumatol 2, Genoa, ItalyDuke Univ, Durham, NC 27706 USAEmory Univ, Sch Med, Atlanta, GA 30322 USAUniv Med Ctr Utrecht, Wilhelmina Childrens Hosp, Utrecht, NetherlandsHannover Med Sch, Hannover, GermanyUniv Estadual Paulista, Sao Paulo, BrazilSemmelweis Univ, Budapest, HungaryRoyal Hosp Sick Children, Glasgow, Lanark, ScotlandRoyal Hosp Sick Children, Edinburgh, Midlothian, ScotlandKarolinska Univ Hosp, Stockholm, SwedenHosp Pediatria Garrahan, Buenos Aires, DF, ArgentinaIst Giannina Gaslini, PRINTO, Pediatria Reumatol 2, Genoa, ItalyCharles Univ Prague, Prague, Czech RepublicUniv Estadual Paulista, Sao Paulo, BrazilIntramural NIH HHS: ZIA ES101081-13Intramural NIH HHS: ZIA ES101081-14Intramural NIH HHS: Z99 ES999999Intramural NIH HHS: ZIA ES101081-15Intramural NIH HHS: ZIA ES101081-12Bmj Publishing GroupNIHUniv PittsburghIst Giannina GasliniSocial & Sci Syst IncHosp Sick ChildrenIWK Hlth CtrUniv FlorenceUniv Buenos AiresUniversidade Federal do Rio de Janeiro (UFRJ)Univ KansasGreat Ormond St Hosp Sick ChildrenUniv Texas DallasUniv GenoaDuke UnivEmory UnivUniv Med Ctr UtrechtHannover Med SchUniversidade Estadual Paulista (Unesp)Semmelweis UnivRoyal Hosp Sick ChildrenKarolinska Univ HospHosp Pediatria GarrahanCharles Univ PragueRider, Lisa G.Aggarwal, RohitPistorio, AngelaBayat, NastaranErman, BrianFeldman, Brian M.Huber, Adam M.Cimaz, RolandoCuttica, Ruben J.Oliveira, Sheila Knupp deLindsley, Carol B.Pilkington, Clarissa A.Punaro, MarilynnRavelli, AngeloReed, Ann M.Rouster-Stevens, Kellyvan Royen-Kerkhof, AnnetDressler, FrankMagalhaes, Claudia Saad [UNESP]Constantin, TamasDavidson, Joyce E.Magnusson, BoRusso, RicardoVilla, LucaRinaldi, MariangelaRockette, HowardLachenbruch, Peter A.Miller, Frederick W.Vencovsky, JiriRuperto, NicolinoInt Myositis Assessment Clinical SPaediat Rheumatology Int Trials O2018-11-28T06:57:31Z2018-11-28T06:57:31Z2017-05-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10application/pdfhttp://dx.doi.org/10.1136/annrheumdis-2017-211401Annals Of The Rheumatic Diseases. London: Bmj Publishing Group, v. 76, n. 5, 10 p., 2017.0003-4967http://hdl.handle.net/11449/16553110.1136/annrheumdis-2017-211401WOS:000398387200005WOS000398387200005.pdfWeb of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengAnnals Of The Rheumatic Diseases7,699info:eu-repo/semantics/openAccess2023-12-29T06:21:37Zoai:repositorio.unesp.br:11449/165531Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462023-12-29T06:21:37Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative |
title |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative |
spellingShingle |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative Rider, Lisa G. |
title_short |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative |
title_full |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative |
title_fullStr |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative |
title_full_unstemmed |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative |
title_sort |
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative |
author |
Rider, Lisa G. |
author_facet |
Rider, Lisa G. Aggarwal, Rohit Pistorio, Angela Bayat, Nastaran Erman, Brian Feldman, Brian M. Huber, Adam M. Cimaz, Rolando Cuttica, Ruben J. Oliveira, Sheila Knupp de Lindsley, Carol B. Pilkington, Clarissa A. Punaro, Marilynn Ravelli, Angelo Reed, Ann M. Rouster-Stevens, Kelly van Royen-Kerkhof, Annet Dressler, Frank Magalhaes, Claudia Saad [UNESP] Constantin, Tamas Davidson, Joyce E. Magnusson, Bo Russo, Ricardo Villa, Luca Rinaldi, Mariangela Rockette, Howard Lachenbruch, Peter A. Miller, Frederick W. Vencovsky, Jiri Ruperto, Nicolino Int Myositis Assessment Clinical S Paediat Rheumatology Int Trials O |
author_role |
author |
author2 |
Aggarwal, Rohit Pistorio, Angela Bayat, Nastaran Erman, Brian Feldman, Brian M. Huber, Adam M. Cimaz, Rolando Cuttica, Ruben J. Oliveira, Sheila Knupp de Lindsley, Carol B. Pilkington, Clarissa A. Punaro, Marilynn Ravelli, Angelo Reed, Ann M. Rouster-Stevens, Kelly van Royen-Kerkhof, Annet Dressler, Frank Magalhaes, Claudia Saad [UNESP] Constantin, Tamas Davidson, Joyce E. Magnusson, Bo Russo, Ricardo Villa, Luca Rinaldi, Mariangela Rockette, Howard Lachenbruch, Peter A. Miller, Frederick W. Vencovsky, Jiri Ruperto, Nicolino Int Myositis Assessment Clinical S Paediat Rheumatology Int Trials O |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
NIH Univ Pittsburgh Ist Giannina Gaslini Social & Sci Syst Inc Hosp Sick Children IWK Hlth Ctr Univ Florence Univ Buenos Aires Universidade Federal do Rio de Janeiro (UFRJ) Univ Kansas Great Ormond St Hosp Sick Children Univ Texas Dallas Univ Genoa Duke Univ Emory Univ Univ Med Ctr Utrecht Hannover Med Sch Universidade Estadual Paulista (Unesp) Semmelweis Univ Royal Hosp Sick Children Karolinska Univ Hosp Hosp Pediatria Garrahan Charles Univ Prague |
dc.contributor.author.fl_str_mv |
Rider, Lisa G. Aggarwal, Rohit Pistorio, Angela Bayat, Nastaran Erman, Brian Feldman, Brian M. Huber, Adam M. Cimaz, Rolando Cuttica, Ruben J. Oliveira, Sheila Knupp de Lindsley, Carol B. Pilkington, Clarissa A. Punaro, Marilynn Ravelli, Angelo Reed, Ann M. Rouster-Stevens, Kelly van Royen-Kerkhof, Annet Dressler, Frank Magalhaes, Claudia Saad [UNESP] Constantin, Tamas Davidson, Joyce E. Magnusson, Bo Russo, Ricardo Villa, Luca Rinaldi, Mariangela Rockette, Howard Lachenbruch, Peter A. Miller, Frederick W. Vencovsky, Jiri Ruperto, Nicolino Int Myositis Assessment Clinical S Paediat Rheumatology Int Trials O |
description |
To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (>= 30), moderate (>= 45), and major (>= 70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p= 0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p< 0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-05-01 2018-11-28T06:57:31Z 2018-11-28T06:57:31Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1136/annrheumdis-2017-211401 Annals Of The Rheumatic Diseases. London: Bmj Publishing Group, v. 76, n. 5, 10 p., 2017. 0003-4967 http://hdl.handle.net/11449/165531 10.1136/annrheumdis-2017-211401 WOS:000398387200005 WOS000398387200005.pdf |
url |
http://dx.doi.org/10.1136/annrheumdis-2017-211401 http://hdl.handle.net/11449/165531 |
identifier_str_mv |
Annals Of The Rheumatic Diseases. London: Bmj Publishing Group, v. 76, n. 5, 10 p., 2017. 0003-4967 10.1136/annrheumdis-2017-211401 WOS:000398387200005 WOS000398387200005.pdf |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Annals Of The Rheumatic Diseases 7,699 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
10 application/pdf |
dc.publisher.none.fl_str_mv |
Bmj Publishing Group |
publisher.none.fl_str_mv |
Bmj Publishing Group |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1792962206132862976 |